Santen Pharmaceutical Co., Ltd. (4536.T) JPX
Currency In JPY
- General
- Statistics
- Historical Data
- Profile
- Financials
Santen Pharmaceutical Co., Ltd.
Address
Grand Front Osaka Tower A
Osaka, OS 530-8552
Japan
Phone
81 6 7664 8621
Website
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
3968
First IPO Date
January 04, 2001
Key Executives
| Name | Title | Pay | Year Born |
| Takeshi Ito | President, Chief Executive Officer & Representative Director | 172M | 1959 |
| Takeshi Matsugi | Head of R&D Strategic Operations | 0 | N/A |
| Chris Hoffman | Group Manager of Corporate Communications Group | 0 | N/A |
| Giyomu Sakuma | Manager of Investor Relations | 0 | N/A |
| Tomohisa Watanabe | Corporate Officers & Global Head of Corporate Strategy | 0 | N/A |
| Tomoyuki Yoshida | Head of Asia Business & Corporate Officer | 0 | N/A |
| Yoshinori Watanabe | Corporate Officer and Head of Sales & Marketing Division OTC products | 0 | N/A |
| Kenji Morishima | Corporate Officer & Head of China Product Development Department | 0 | N/A |
| Rie Nakajima | Chief Operating Officer, Corporate Officer & Director | 0 | 1977 |
| Yoko Saiki | Corporate Officer & Chief Human Resources Officer | 0 | N/A |
| Daisuke Nakata | Chief Digital & Information Officer | 0 | N/A |
| Takahiro Morita | Global Head of Core Principle & Sustainability and Corporate Officer | 0 | N/A |
| Kazuo Koshiji | Chief Financial Officer & Corporate Officer | 0 | N/A |
| Kaori Itagaki | General Manager of Investor Relations Group | 0 | N/A |
| Mika Masunari | Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer | 0 | N/A |
| Shinichi Teramachi | Corporation Officer, Head of Sales and Head of Japan Sales & Marketing | 0 | N/A |
Description
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
